Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078470 | 0.72 | OPRM1 (0.33) | — | |
| SCHEMBL7070791 | 0.72 | ESR2 (0.38) | ESR1ESR2CA1CA2CA7 | |
| SCHEMBL7076088 | 0.70 | SHBG (0.33) | KDM4EALDH1A1 | |
| SCHEMBL7078445 | 0.69 | PBRM1 (0.36) | ESR1ESR2CA1CA2CA7 | |
| SCHEMBL6800177 | 0.64 | ESR2 (0.38) | KDM4EALDH1A1ESR1ESR2CA1 | |
| SCHEMBL6797067 | 0.56 | MAOA (0.43) | KDM4EALDH1A1ESR1CA1CA2 | |
| SCHEMBL11631602 | 0.56 | CYP19A1 (0.44) | KDM4EALDH1A1ESR1ESR2 | |
| SCHEMBL7072886 | 0.56 | — | — | |
| SCHEMBL6802036 | 0.55 | DYRK1A (0.33) | KDM4EALDH1A1ESR1ESR2 | |
| SCHEMBL6802032 | 0.55 | DYRK1A (0.33) | KDM4EALDH1A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339662-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002046134-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2002-06-13 | — | — | WO | disclosed |